Hematological toxicity associated with tiazofurin-influence on erythropoiesis

Toxicology Letters

Volumn 114, Issue 1-3, 2000, Pages 81-90

  Vranić, Vesna ^a   Savovski, Kiril ^a   Dedović, Nasta ^a   Dimitrijević, Bogomir ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cellularity of bone marrow and spleen; Erythropoiesis; Hematological toxicity; Tiazofurin

Indexed keywords

TIAZOFURIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD TOXICITY; BONE MARROW TOXICITY; CELL DENSITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ERYTHROPOIESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; TECHNIQUE;

ALOPECIA; ANEMIA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD CELL COUNT; BLOOD CELLS; BONE MARROW CELLS; CACHEXIA; CELL COUNT; COMA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIESIS; HEMATOCRIT; HEMOGLOBINS; LUNG; MALE; RATS; RATS, WISTAR; RIBAVIRIN; SPLEEN; SPLENOMEGALY; SURVIVAL RATE;

EID: 0034599384     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00269-6     Document Type: Article

References (23)

1. Ahluwalia S., Jayaram H.N., Plowman J.P., Cooney D.A., Jones D.J. Studies of the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide-V. Factors govering the response of murine tumors totiazofurin. Biochem. Pharmacol. 33:1984;1195-1203.
2. Balducci L., Hardy C.L. Advanced Lewis lung carcinoma cured by tiazofurin as a system to study delayed hemopoietic effects of cancer. Cancer Inves. 6(6):1988;681-686.
3. Batist G., Klecker R.W., Jayaram H.N., Jeniks J.F., Grygiel J., Ihde D.C., Eddy G.L., Fine R.L., Ker I.G., Collins J.M. Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286 193) administered by continuous infusion. Invest. New Drugs. 3:1985;349-355.
4. Diehl L.F., Bolan C.D., Raymond B.W. Hemolytic anemia and cancer. Cancer Treat. Rev. 22:1996;33-73.
5. Goldstein B.M., Leary J.F., Farley B.A., Marqez V.E., Levy P.C., Rowley P.T. Induction of HL 60 cell differentiation by tiazofurin and its analogues: caracterization and efficacy. Blood. 78(3):1991;593-598.
6. Green R.M., Stewart D.J., Maroun J.A. Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286 193). Invest. New Drugs. 4:1986;387-394.
7. Grem J.L. Clinical toxicity associated with tiazofurin. Invest. New Drugs. 8:1990;227-238.
8. Harrison D., Lerner C. Most primitive hematopoetic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood. 78(5):1991;1237-1240.
9. Hata Y., Natsumeda Y., Weber G. Tiazofurin decreases Ras-GTP complex in K562 cells. Oncol. Res. 5:1993;161-164.
10. Jayaram H.N., Pillwein K., Nichols C.R., Hoffman R., Weber G. Selective sensitivity to tiazofurin of human leukemic cells. Biochem. Pharmacol. 35:1986;2029-2032.
11. Jayaram H.N., Lapis E., Tricot J., Kneebone P., Paulik E., Zhen W., Engeler G.P., Hoffman R., Weber G. Clinical pharmacokinetic study of tiazofurin administred as a 1-hour infusion. Intl. J. Cancer. 51(2):1992;182-188.
12. Lapis K., Bocsi J., Tóvári J., Bartha I., Timár J., Rásó E. Antiinvasive effects of tiazofurin on liver-metastatic human colon carcinoma xenografts. Anticancer Res. 16:1996;3323-3332.
13. Lerner C., Harrison D. 5-Fluorouracil spares hemopoetic stem cell responsible for long term repopulation. Exp. Hematol. 18:1990;114-118.
14. Maroun J.A., Stewart D.J. Phase I Study of Tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide NSC 286 193). Invest. New Drugs Suppl. 1:1990;33-39.
15. Milutinović, D. Tiazofurin acute parenteral (i.p.) toxicity in rats. (Research report) ICN GALENIKA, Belgrade, 1995.
16. Monks A., Marquez V.R., Mao D.T., Cysyk R.L. Uptake of 2-β-D-ribofuranosylthiazole-4-carboxamide-(Tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. Cancer Lett. 28:1985;1-8.
17. Nagai M., Natsumeda J., Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 52:1992;258-261.
18. Prajda N., Hata Y., Abonyi M., Singhal R.L., Weber G. Sequential impact of tiazofurin and ribavirin on the enzymic program of rat bone marrow. Cancer Res. 53(24):1993;5982-5986.
19. Rásó E., Lapis K. Inhibition of progresion of human and rat Wilms' tumor by tiazofurin. Anticancer Res. 16:1996;3333-3340.
20. Savovski K., Pujić N., Vranić V., Dimitrijević B. Effects of modified CMF (cyclophosphamide, methotrexate and 5-fluorouracil) treatment on hematopoietic tissues and Yoshida sarcoma in rats. Acta Oncol. 33(7):1994;793-798.
21. Tóvári J., Bocsi J., Ladányi A., Lapis K., Timár J. The antitumor effect of tiazofurin (TR) consist of anti-proliferative and anti-invasive elements. Anticancer Res. 16:1996;3307-3312.
22. Tricot G., Weber G. Bichemicaly targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocyticleukemia with tiazofurin, a selective bloker of inosine 5′-phosphate dehydrogenase activity. Anticancer Res. 16:1996;3341-3348.
23. Wintrobe M.M., Lee G.R., Boggs D.R., Bithell T.C., Foerster J., Athens J.W., Lukens J.N. Clin. Hematol. 8th edition:1981;Lee & Febiger, Philadelphia.